Colgate's Bright Smile: Analyst Envisions Upswing In 2024 Guidance With Ample Growth Opportunities
Colgate's Bright Smile: Analyst Envisions Upswing In 2024 Guidance With Ample Growth Opportunities
Raymond James analyst Olivia Tong upgraded Colgate-Palmolive Co (NYSE:CL) to Outperform from Market Perform and announced a $91 price target.
雷蒙德·詹姆斯分析師奧利維亞·湯將高露潔棕欖公司（紐約證券交易所代碼：CL）從市場表現上調至跑贏大盤，並宣佈了91美元的目標股價。
The analyst is bullish on the stock following strong fourth-quarter FY23 earnings and the introduction of the 2024 outlook.
繼23財年第四季度收益強勁以及2024年展望公佈之後，該分析師看好該股。
The oral care giant reported fourth-quarter FY23 sales growth of 7% year-on-year to $4.95 billion, beating the analyst consensus estimate of $4.89 billion and Base Business (non-GAAP) EPS of $0.87, beating the analyst consensus of $0.80.
這家口腔護理巨頭報告稱，23財年第四季度銷售額同比增長7％，達到49.5億美元，超過了分析師共識估計的48.9億美元和基礎業務（非公認會計准則）每股收益0.87美元，超過了分析師共識的0.80美元。
The company expects FY24 net sales growth to be 1%-4%, including a low-single-digit negative impact from foreign exchange.
該公司預計，24財年的淨銷售額將增長1％-4％，其中包括來自外匯的低個位數負面影響。
The analyst writes that the 2024 EPS outlook was below their expectations at the midpoint, leaving ample room for the company to boost guidance expectations as the year progresses.
該分析師寫道，2024年的每股收益展望在中點低於他們的預期，這爲公司隨着年度的推移提高指導預期留出了充足的空間。
The analyst says that Colgate-Palmolive is still in the early innings of improved top and bottom-line growth, balancing contribution from volume vs price, emerging markets vs developed, and across the product portfolio.
這位分析師表示，高露潔棕欖仍處於收入和利潤增長改善的初期，平衡了銷量與價格、新興市場與發達市場以及整個產品組合的貢獻。
Tong expects the company to continue to drive sales growth ahead of its long-term target ranges and towards the upper end of peers, led by innovation, continued premiumization in Oral Care, and increased category penetration for Hill's countering decelerating pet category growth.
Tong預計，在創新、口腔護理持續優質化以及Hill對抗寵物品類增長減速所帶來的品類滲透率提高的帶動下，該公司將繼續推動銷售增長，超出其長期目標區間並邁向同行的高端。
The analyst maintained 2024 estimates for organic sales growth at +5% (+4% reported) and EPS at $3.46 (towards the company guidance's upper end).
該分析師將2024年的有機銷售增長預期維持在+5％（報告爲+4％），每股收益維持在3.46美元（接近公司預期的上限）。
Tong projects volumes to be flat in the first quarter but turn positive starting the second quarter, pricing to be an outsized contributor for most of 2024, continued tailwinds for gross margin, and improvement in North American share.
Tong預計，第一季度的銷量將持平，但從第二季度開始轉爲正數，定價將在2024年大部分時間內成爲巨大貢獻者，毛利率將持續走向順風，北美份額將有所改善。
However, the analyst sees risks in Latin America business from Argentina in FY24, which is expected to be more than offset by strength in Mexico and Brazil.
但是，該分析師認爲，在24財年，阿根廷在拉丁美洲的業務面臨風險，墨西哥和巴西的強勁勢頭預計將足以抵消這一風險。
Apart from this, Wells Fargo analyst Chris Carey raised the price target to $88 from $80 and reaffirmed an Equal-Weight rating.
除此之外，富國銀行分析師克里斯·凱里將目標股價從80美元上調至88美元，並重申了等權評級。
Also, UBS analyst Peter Grom raised the price target to $95 from $93 and reiterated a Buy rating, and Morgan Stanley analyst increased the price target to $93 from $85 and maintained an Overweight rating.
此外，瑞銀分析師彼得·格羅姆將目標股價從93美元上調至95美元，並重申了買入評級，摩根士丹利分析師將目標股價從85美元上調至93美元，並維持增持評級。
Price Action: CL shares are up 0.96% at $83.63 on the last check Monday.
價格走勢：週一的最後一次支票中，CL股價上漲0.96％，至83.63美元。
Photo by thetaxhaven via Flickr
照片由 thetaxhaven 通過 Flickr 拍攝
譯文內容由第三人軟體翻譯。